Comparison of Clinical Prognosis of Chemo-Radiotherapy and Surgical Treatment for Patients with Limited Stage Small Cell Lung Cancer after Matching

Chen Mengyuan,Hu Xiao,Qi Xiaofang,Xu Yujin,Dong Baiqiang,Chen Yamei,Chen Ming

DOI: https://doi.org/10.3760/cma.j.issn.1004-4221.2019.11.005

2019-01-01

Abstract:Objective To compare the overall survival (OS),progression-free survival (PFS) and brain metastasis free survival (BMFS) between the chemo-radiotherapy and surgical treatment for patients with limited stage small cell lung cancer (LS-SCLC).Methods Clinical data of 69 patients diagnosed with LS-SCLC undergoing surgery in Zhejiang Cancer Hospital between 2000 and 2016 were collected.According to T,N stage,treatment duration,age,gender and whether or not prophylactic cranial irradiation (PCI),69 patients of 503 LS-SCLC patients who underwent standard radiochemotherapy were assigned into the radiochemotherapy group by using the pair-matched case-control method.Results Among 138 patients,69 cases were allocated into the surgery group (24 cases of stage Ⅰ,14 cases of stage Ⅱ and 31 cases of stage Ⅲ) and 69 cases in the radiochemotherapy group (24 cases of stage Ⅰ,14 cases of stage]Ⅱ and 31 cases of stage Ⅲ).The median OS time was 37.1 months (95％CI:24.1-50.2 months) in surgery group and 45.0 months (95％CI:15.8-74.2 months) in the radiochemotherapy group.The 2-and 5-year OS rates were 60％ and 45％ in the surgery group,and 64％ and 45％ in the radiochemotherapy group (P=0.846).The median PFS time was 27.1 months (95％CI:0.00-60.3 months) in the surgery group and 36.2 months (95％CI:20.9-51.4 months) in the radiochemotherapy group.The 2-and 5-year PFS rates were 52％,and 38％ in the surgery group,and 56％ and 40％ in the chemo-radiotherapy group (P=0.610).The 2-and 5-year BMFS rates were 81％ and 76％ in the surgery group,and 84％ and 80％ in the radiochemotherapy group (P=0.774).The 5-year OS rate (62％ vs.40％,P=0.038) and 5-year PFS rate (80％ vs.40％,P=0.048) for patients with stage Ⅰ LS-SCLC in the surgery group were significantly higher than those in the radiochemotherapy group.However,the 5-year BMFS rate in patients with stage Ⅰ LS-SCLC did not significantly differ between two groups (92％ vs.95％,P=0.816).The 5-year OS rate (41％ vs.51％,P=0.946),5-year PFS rate (65％ vs.42％,P=0.280) and 5-year BMFS rate (75％ vs.78％,P=O.720) for stage Ⅱ SCLC did not significantly differ between two groups.As for stage Ⅲ SCLC patients,the OS rate (25％ vs.48％,P=0.220),5-year PFS rate (28％ vs.36％,P=0.333) and 5-year BMFS rate (76％ vs.74％,P=0.84) did not significantly differ between two groups.Conclusions Surgical treatment can bring survival benefits to patients with stage Ⅰ LS-SCLC.The survival prognosis of stage [[patients is equivalent between two groups.Patients with stage Ⅲ LS-SCLC receiving radiochemotherapy obtain better survival trend compared with those undergoing surgery.The conclusion remains to be validated by studies with larger sample size or prospective investigations.